Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Background: The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who...
| Publicado en: | BMC Urology Vol. 16; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
BioMed Central
2/29/2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113987950&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 113987950 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14712490 1CIO jtl: BMC Urology issn: 14712490 maglogo: N pubinfo: dt: 2/29/2016 vid: 16 pid: 24147 pub: BioMed Central artinfo: ui: 113987950 113987950 NLM26928323 113987950 10.1186/s12894-016-0128-8 NLM26928323 PMC4772680 113987950 ppf: 1 ppct: 10 formats: tig: atl: Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. aug: au: Alinezhad, Saeid Väänänen, Riina-Minna Ochoa, Natalia Tong Vertosick, Emily A. Bjartell, Anders Boström, Peter J. Taimen, Pekka Pettersson, Kim affil: Division of Biotechnology, University of Turku, Tykistökatu 6A 6th floor, 20520 Turku, Finland sug: subj: Receptors, Cell Surface Adenocarcinoma Prostatic Neoplasms Prostate Metabolism Enzymes Prostate-Specific Antigen Blood Coagulation Factors RNA Metabolism Middle Age Prostatectomy Adenocarcinoma Metabolism Blood Coagulation Factors Metabolism Human Male Aged Receptors, Cell Surface Metabolism Neoplasm Staging Prostate-Specific Antigen Metabolism Immunohistochemistry Prostatic Neoplasms Metabolism Enzymes Metabolism Neoplasm Grading Reverse Transcriptase Polymerase Chain Reaction Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source Middle Aged: 45-64 years Aged: 65+ years Male ab: Background: The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.Methods: AMACR and AR mRNA levels were measured with quantitative, reverse-transcription PCR (qRT-PCR) assays in 79 radical prostatectomy (RP) cases (including 69 benign (RP-Be) and 69 cancerous (RP-PCa) samples) and 19 benign prostate samples obtained from cystoprostatectomies. To further determine the detailed areas of altered AMACR expression, AMACR mRNA level measurement and protein staining were performed for three cross-sectioned RP cases.Results: The median AMACR and AR expression levels were 194.6 (p < 0.0001) and 6.6 (p = 0.0004) times higher in RP-PCa samples than in the benign cystoprostatectomy (CP) samples, respectively. There was no statistically significant difference between RP-PCa and RP-Be samples, except for AMACR/KLK3 (Kallikrein-Related Peptidase 3) ratio, which was significantly higher in RP-PCa samples than in RP-Be samples (p = 0.016). In the systematic study of cross-sections, AMACR mRNA was detected in all of the studied areas including histologically benign tissue, but at significantly higher levels in carcinoma areas (p < 0.001). AMACR protein expression was detected in 80 % (28/35) of the areas that contained carcinoma and in 37 % (44/119) of the benign and PIN areas from the same patients.Conclusions: AMACR transcripts were detected in all RP-PCa and RP-Be samples but not in non-cancerous CP samples, which suggest a global increase of AMACR expression in cancerous prostates. Therefore patients with false negative biopsies might benefit from an AMACR mRNA measurement when assessing their cancer risk. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|